NCT07516392Not yet recruiting
Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma
PRE-PDAC: Evaluation of Polygenic Risk scorE for Pancreatic Ductal AdenoCarcinoma Risk Prediction: a Case-control Study
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
This case-control study aims to evaluate the role of a polygenic risk score in predicting the risk of pancreatic ductal adenocarcinoma (PDAC). The study will compare genetic risk profiles between individuals with PDAC and controls without the disease in order to assess whether a polygenic risk score may help identify individuals at higher risk. The findings may contribute to improving risk stratification and supporting future strategies for early identification and prevention of pancreatic cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1140 (estimated)
- First submitted
- 18 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- Jul 2026
- Lead sponsor
- Catholic University of the Sacred Heart
- Diseases
- Pancreatic cancer
- NCT number
- NCT07516392
What you commit to
- Study type: Interventional
- Planned participants: 1140
- From Apr 2026 to the primary completion date, Jul 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that, in the judgment of the investigators, makes the participant unsuitable for inclusion
Age
- Age younger than 18 years.
Other
- Inability to provide informed consent.
- Incomplete or unavailable clinical and/or biological data required for the study.
Who the study is looking for
- Adults aged 18 years and older.
- Able and willing to provide informed consent.
- For cases: participants with pancreatic ductal adenocarcinoma.
- For controls: participants without pancreatic ductal adenocarcinoma.
- Availability of the clinical and/or biological data required for the study, including data necessary for polygenic risk score evaluation.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.